17,261 trials
Carcinoma, Non-Small-Cell Lung
Primary: 6-month Progression-free Survival — 30.7; 26.4 Percentage of Patients
Coronary Disease
Primary: Number of Participants Displaying the Composite of Major and Clinically Relevant Minor Bleeding Events During Total Observation Time — 13; 16; 32; 27 participants…
Leukemia · Myelodysplastic Syndromes
Primary: Number of Patients Experiencing Regimen-related Toxicity Events in Study Population — 2; 5 participants
Smallpox
Primary: The Neutralizing Antibody Response Titers Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine — 77; 112; 76; 91 PRNT50 Titers
Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD)
Primary: Mean Change From Baseline in the Best Corrected Visual Acuity Score of the Study Eye at Month 6 in Group B — 47.6; 48.1; 55.7; 57.1 Number of Letters
Smallpox
Primary: Number of Participants Reporting Adverse Events of Severe Intensity Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine — 2; 4; 3; 4 Participants
Atrial Fibrillation
Primary: Number of Participants With Fatal or Life-threatening Major Bleeding Events — 0; 0; 0; 0 Participants
Asthma · Airway Inflammation
Primary: Mean Percent Change From Baseline to Day 14 in Exhaled Nitric Oxide (eNO) Parts Per Billion (Ppb) — -35.3; -45.4; -61.4; -51.3 percentage of eNO — p=<0.001
Vulvodynia
Primary: Mean Marinoff Dyspareunia Scale Score (MDSS) at End of Treatment (12 Weeks) — 1.8; 1.8; 1.7 scores on a scale
End-Stage Renal Disease (ESRD)
Primary: Percent of Subjects Whose Hemoglobin (Hgb) Decreases by a Total of 1.0 Grams/ Deciliter (g/dL) (or More) From Baseline on Each of Two Successive Measurements. — 5; 6; 5…
Recurrent Small-cell Lung Cancer (SCLC) · Lung Cancer, Small Cell
Primary: Percentage of Participants With Progression-free Survival (PFS) at 3 Months — 65 percentageof participants — p=0.017
Acute Myelogenous Leukemia · Chemotherapy-induced Nausea and Vomiting
Primary: Number of Patients With Complete Response — 11; 15; 18 participants
Esophageal Cancer
Primary: Number of Participants With Overall Response Rate (RR) — 44 participants
Post Acute Coronary Syndrome · Myocardial Ischemia
Primary: Change From Baseline in N-terminal proB-type Natriuretic Peptide (NT-proBNP) at Week 8 — 0.582; 0.563; 0.614; 0.635 pg/mL
Candidiasis · Candidemia
Primary: Area Under the Curve Over Dosing Interval at Steady State (AUC12,ss) Following IV Administration — 21.42 μg*h/mL